|
UCN-01 and Fludarabine to Treat Lymphoma and Leukemia Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about UCN-01 and Fludarabine to Treat Lymphoma and Leukemia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. UCN-01 and Fludarabine to Treat Lymphoma and Leukemia Clinical research trials and UCN-01 and Fludarabine to Treat Lymphoma and Leukemia health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including UCN-01 and Fludarabine to Treat Lymphoma and Leukemia. UCN-01 and Fludarabine to Treat Lymphoma and Leukemia Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a UCN-01 and Fludarabine to Treat Lymphoma and Leukemia clinical trial. Test subjects typically receive the most expert healthcare available for their UCN-01 and Fludarabine to Treat Lymphoma and Leukemia condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "U" Clinical Trials Conditions > UCN-01 and Fludarabine to Treat Lymphoma and Leukemia  UCN-01 and Fludarabine to Treat Lymphoma and Leukemia
UCN-01 and Fludarabine to Treat Lymphoma and Leukemia
For Condition: Chronic Lymphocytic Leukemia,Hairy Cell Leukemia,Leukemia,Lymphoma,Waldenstrom Macroglobulinemia
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study will test the safety and effectiveness of UCN-01, an experimental drug, together with fludarabine, a standard treatment for low-grade lymphomas and leukemias, in treating these cancers. Laboratory studies have shown that UCN-01 inhibits (slows or prevents) tumor cell growth and may also destroy some cells. Laboratory studies have also shown that when UCN-01 was combined with fludarabine, it increased fludarabine's effectiveness as much as 10 times. Patients with low-grade relapsed lymphoma or leukemia who are candidates for this study will undergo various tests. These may include blood tests, X rays, CT and MRI scans, nuclear medicine scans, and bone marrow biopsy and aspiration to determine the extent of the patient's disease. For those accepted to the study, some or all of these tests will be repeated at various times during the study, for up to two years after treatment is completed. Treatment will consist of up to six courses, or cycles, of UCN-01 and fludarabine given in combination. Each patient will first receive UCN-01 alone to determine if it is safe for that patient. Then, UCN-01 and fludarabine will be given together. UCN-01 will be infused through a vein over a period of 36 hours (except for the first course, which will take 72 hours) and fludarabine will be infused over 30 minutes. Fludarabine will be given from one to five days, starting the same day the UCN-01infusion begins. The cycle is repeated at four-week intervals. Patients may also be asked to undergo additional bone marrow biopsy and aspirations and apheresis-a procedure to remove white blood cells-for research purposes, but these tests are not required to participate in the study.
Details: We are interested in identifying agent(s) that may decrease the threshold for cytotoxic-induced apoptosis. The novel staurosporine analog, 7-hydroxystaurosporine (UCN-01: NSC 638850), appears to increase cytotoxic-induce apoptosis, and thus may decrease the threshold for apoptosis. UCN-01 is a non-specific protein and tyrosine kinase inhibitor that regulates signal transduction, and is synergistic in vitro with a number of chemotherapy agents. Thus, UCN-01 may augment the activity of chemotherapy in drug resistant patients. To begin to assess this, we wish to assess the tolerance of UCN-01 and fludarabine in patients with relapsed indolent lymphoid malignancies. We have selected indolent lymphomas based on the clinical evidence that as a group, they are responsive to fludarabine. The study will be a phase I and pharmacokinetic study. Patients will initially receive 1 cycle of UCN-01 alone to allow measurement of PK and other scientific endpoints. Leukopheresis for normal T-cells in patients without leukemias and for circulating tumor cells in patients with leukemias will be performed and analyzed by gene chip technology for alterations in mRNA expression and kinase activity. Furthermore, FACS analysis for CD4, CD8, CD45RO, CD4RA will be performed before and after 1 cycle of UCN-01 to assess effects on T-cell number and distribution. Following 1 cycle of UCN-01 alone, patients will crossover to receive UCN-01 and fludarabine beginning on cycle 2. PK of UCN-01 and fludarabine will be repeated when the combination is administered. Furthermore, gene chip and FACS analysis would be performed during the combination cycles as well.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Relapsed or refractory low-grade lymphoid malignancies (follicular small cleaved-grade I/II subtypes; marginal zone-nodal/extranodal/ splenic subtypes; small lymphocytic-lymphoma/leukemia subtypes (CLL); Waldenstrom's macroglobulinemia, mantle cell; lymphoplasmacytoid; Hairy cell leukemia. Patients with transformed indolent subtypes are eligible providing they have previously received a doxorubicin-containing regimen or do not have rapidly progressive disease that threatens vital functions. Histology confirmed by Laboratory of Pathology, NCI. Requires systemic therapy. Performance Status greater than or equal to 60%. Age 18 years or older. Creatinine less than 1.5 mg/dl or creatinine clearance greater than 60 ml/min; total bilirubin less than 2.0 mg/dl (patients with elevation of total bilirubin consistent with Gilbert's disease are eligible providing they have a normal direct bilirubin); ANC greater than or equal to 1000/mm(3); and platelet greater than or equal to 80,000/mm(3). Measurable disease. Recovered from acute effects of prior therapy. Provides signed informed consent. EXCLUSION CRITERIA: HIV positive serology. Pregnant or nursing. The effects of these agents on an unborn or breastfeeding child are unknown. Because there is a risk of detrimental effects on an unborn or breastfeeding child, pregnant or nursing women will be excluded fpr the study. Both male and female patients must be willing to use adequate contraception. Active leptomeningeal or parenchymal CNS lymphoma. Active Coombs + hemolytic anemia. Systemic chemotherapy or systemic steroids within 3 weeks of study entry. Diabetes mellitus requiring insulin treatment. History of active coronary artery disease (defined by angina, congestive heart failure or myocardial infarction with 6 months).
Total Enrollment: 20
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Clinical Support Center/NCI 1-888-624-1937
Additional Information:
Study ID Numbers: 990127; 99-C-0127
Study Start Date: July 12, 1999
Record last reviewed: June 1, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001822
Other Lymphoma Studies:
1. Melphalan in Patients With Neoplastic Meningitis
2. VNP40101M in Treating Patients With Advanced or Metastatic Cancer
3. Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
4. Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
5. Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
Related Studies:
Other Lymphoma Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
UCN-01 and Fludarabine to Treat Lymphoma and Leukemia
|
|
|
|
|
|
|
|
